For instance, miR-146a, downregulated in the blood of AD patients, represses the expression of neurofilament light chains (NfL), which are reported to be increased several years before the onset of clinical symptoms in individuals carrying a mutation in the APP, PSEN1 or PSEN2 familial AD genes (8, 9). Here, NEFL is linked to Alzheimer disease.